"As an all-inclusive practice, NJU is dedicated to providing comprehensive individualized treatment for all patients."

During the past decade, New Jersey Urology, LLC conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 7 clinical trials were completed, i.e. on average, 28% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 3 clinical trials were completed. i.e. 21.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New Jersey Urology, LLC" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Exosome Diagnostics, Inc." with 3 trials sponsored, "Bayer" with 2 trials sponsored, "Bioniche Life Sciences Inc." with 2 trials sponsored and "Spectrum Pharmaceuticals, Inc" with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New Jersey Urology, LLC" #1 collaborator was "Allergan" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "ClinLogix. LLC" with 1 trials as a collaborator, "Endo Pharmaceuticals" with 1 trials as a collaborator and "FKD Therapies Oy" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "New Jersey Urology, LLC" are "Bladder Cancer" (3 trials), "Prostate Cancer" (3 trials), "Urinary Bladder Neoplasms" (3 trials), "Neurogenic Bladder" (2 trials) and "Overactive Bladder" (2 trials). Many other conditions were trialed in "New Jersey Urology, LLC" in a lesser frequency.

Most popular intervention types in "New Jersey Urology, LLC" are "Drug" (22 trials), "Biological" (5 trials), "Device" (5 trials), "Diagnostic Test" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Cetrelimab" (3 trials), "TAR-200" (3 trials), "Apalutamide" (2 trials) and "Apaziquone" (2 trials). Other intervention names were less common.

The vast majority of trials in "New Jersey Urology, LLC" are 17 trials for "Male" genders, 16 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "New Jersey Urology, LLC". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in New Jersey Urology, LLC, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in New Jersey Urology, LLC, 4 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 6 trials that are defined as “Not Applicable".